Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies

References

• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19(16), 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med.353(20), 2135–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer6(9), 714–727 (2006).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon-α 2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N. Engl. J. Med.324(1), 1–8 (1991).
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med.1(1), 27–31 (1995).
   PubMed Web of Science ®Google Scholar
• Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst.84(24), 1875–1887 (1992).
   PubMed Web of Science ®Google Scholar
• Imao T, Egawa M, Takashima H, Koshida K, Namiki M. Inverse correlation of microvessel density with metastasis and prognosis in renal cell carcinoma. Int. J. Urol.11(11), 948–953 (2004).
   PubMed Web of Science ®Google Scholar
• Baldewijns MM, Thijssen VL, Van den Eynden GG et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br. J. Cancer96(12), 1888–1895 (2007).
   PubMed Web of Science ®Google Scholar
• Qian CN, Huang D, Wondergem B, Teh BT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer115(10 Suppl.), 2282–2289 (2009).
   PubMed Web of Science ®Google Scholar
• Busam KJ, Berwick M, Blessing K et al. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am. J. Pathol.147(4), 1049–1056 (1995).
   PubMed Web of Science ®Google Scholar
• Carnochan P, Briggs JC, Westbury G, Davies AJ. The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85–81.25 mm in thickness. Br. J. Cancer64(1), 102–107 (1991).
   PubMed Web of Science ®Google Scholar
• Neitzel LT, Neitzel CD, Magee KL, Malafa MP. Angiogenesis correlates with metastasis in melanoma. Ann. Surg. Oncol.6(1), 70–74 (1999).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med.11(3), 261–262 (2005).
   PubMed Web of Science ®Google Scholar
• St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. Science289(5482), 1197–1202 (2000).
   PubMed Web of Science ®Google Scholar
• Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol. Sci.25(10), 536–542 (2004).
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Jo WS, Duerr EM et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1a-deficient colon cancer cells. Nat. Med.11(9), 992–997 (2005).
   PubMed Web of Science ®Google Scholar
• Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell6(5), 447–458 (2004).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86(3), 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development126(14), 3047–3055 (1999).
   PubMed Web of Science ®Google Scholar
• Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer7(5), 327–331 (2007).
   PubMed Web of Science ®Google Scholar
• van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res.78(2), 203–212 (2008).
   PubMed Web of Science ®Google Scholar
• Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer8(8), 604–617 (2008).
   PubMed Web of Science ®Google Scholar
• Fukumura D, Xavier R, Sugiura T et al. Tumor induction of VEGF promoter activity in stromal cells. Cell94(6), 715–725 (1998).
   PubMed Web of Science ®Google Scholar
• Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res.60(22), 6253–6258 (2000).
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α – hypoxia response element – VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res.60(22), 6248–6252 (2000).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol.19(2), 577–583 (2001).
   PubMed Web of Science ®Google Scholar
• Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer Ther.2(8), 753–763 (2003).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer8(8), 579–591 (2008).
   PubMed Web of Science ®Google Scholar
• Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer2(11), 826–835 (2002).
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med.7(11), 1194–1201 (2001).
   PubMed Web of Science ®Google Scholar
• Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol.265(2 Pt 2), H586–H592 (1993).
   PubMed Web of Science ®Google Scholar
• Mercurio AM, Lipscomb EA, Bachelder RE. Non-angiogenic functions of VEGF in breast cancer. J. Mammary Gland Biol. Neoplasia10(4), 283–290 (2005).
   PubMed Web of Science ®Google Scholar
• Fan F, Wey JS, McCarty MF et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene24(16), 2647–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med.2(10), 1096–1103 (1996).
   PubMed Web of Science ®Google Scholar
• Pisacane AM, Risio M. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res.15(1), 39–43 (2005).
   PubMed Web of Science ®Google Scholar
• Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell92(6), 735–745 (1998).
   PubMed Web of Science ®Google Scholar
• Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem.269(41), 25646–25654 (1994).
   PubMed Web of Science ®Google Scholar
• Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol.20(5–6), 319–325 (2001).
   PubMed Web of Science ®Google Scholar
• Singh H, Milner CS, Aguilar Hernandez MM, Patel N, Brindle NP. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases. Cell. Signal.21(8), 1346–1350 (2009).
   PubMed Web of Science ®Google Scholar
• Hawighorst T, Skobe M, Streit M et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am. J. Pathol.160(4), 1381–1392 (2002).
   PubMed Web of Science ®Google Scholar
• Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci.49(5), 2163–2171 (2008).
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science277(5322), 55–60 (1997).
   PubMed Web of Science ®Google Scholar
• Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler. Thromb. Vasc. Biol.27(12), 2619–2626 (2007).
   PubMed Web of Science ®Google Scholar
• Helfrich I, Edler L, Sucker A et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res.15(4), 1384–1392 (2009).
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Sjoblom T, Abramsson A et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res.64(8), 2725–2733 (2004).
   PubMed Web of Science ®Google Scholar
• Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int. J. Cancer121(12), 2606–2614 (2007).
   PubMed Web of Science ®Google Scholar
• Rundhaug JE. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med.9(2), 267–285 (2005).
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell95(3), 365–377 (1998).
   PubMed Web of Science ®Google Scholar
• Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem.276(40), 37491–37500 (2001).
   PubMed Web of Science ®Google Scholar
• Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J. Invest. Dermatol.115(3), 337–344 (2000).
   PubMed Web of Science ®Google Scholar
• Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res.11(14), 5158–5166 (2005).
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer2(3), 161–174 (2002).
   PubMed Web of Science ®Google Scholar
• Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp. Dermatol.12(2), 109–125 (2003).
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol.2(10), 737–744 (2000).
   PubMed Web of Science ®Google Scholar
• Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J. Cell Sci.115(Pt 17), 3427–3438 (2002).
   PubMed Web of Science ®Google Scholar
• Arroyo AG, Genis L, Gonzalo P, Matias-Roman S, Pollan A, Galvez BG. Matrix metalloproteinases: new routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease. Curr. Pharm. Des.13(17), 1787–1802 (2007).
   PubMed Web of Science ®Google Scholar
• Chun TH, Sabeh F, Ota I et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol.167(4), 757–767 (2004).
   PubMed Web of Science ®Google Scholar
• Iida J, Wilhelmson KL, Price MA et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J. Invest. Dermatol.122(1), 167–176 (2004).
   PubMed Web of Science ®Google Scholar
• Seftor RE, Seftor EA, Koshikawa N et al. Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res.61(17), 6322–6327 (2001).
   PubMed Web of Science ®Google Scholar
• Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer3(6), 411–421 (2003).
   PubMed Web of Science ®Google Scholar
• Yana I, Sagara H, Takaki S et al. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell. Sci.120(Pt 9), 1607–1614 (2007).
   PubMed Web of Science ®Google Scholar
• Sounni NE, Roghi C, Chabottaux V et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem.279(14), 13564–13574 (2004).
   PubMed Web of Science ®Google Scholar
• Sounni NE, Devy L, Hajitou A et al. MT1–MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J.16(6), 555–564 (2002).
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin α v β 3 for angiogenesis. Science264(5158), 569–571 (1994).
   PubMed Web of Science ®Google Scholar
• Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. Integrin signaling is critical for pathological angiogenesis. J. Exp. Med.203(11), 2495–2507 (2006).
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol.140(5), 1255–1263 (1998).
   PubMed Web of Science ®Google Scholar
• Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell79(7), 1157–1164 (1994).
   PubMed Web of Science ®Google Scholar
• Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin α V β 3 during angiogenesis. J. Clin. Invest.98(2), 426–433 (1996).
   PubMed Web of Science ®Google Scholar
• Stromblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem. Biol.3(11), 881–885 (1996).
   PubMed Web of Science ®Google Scholar
• Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol.155(3), 459–470 (2001).
   PubMed Web of Science ®Google Scholar
• Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am. J. Pathol.156(4), 1345–1362 (2000).
   PubMed Web of Science ®Google Scholar
• Boudreau NJ, Varner JA. The homeobox transcription factor Hox D3 promotes integrin α5β1 expression and function during angiogenesis. J. Biol. Chem.279(6), 4862–4868 (2004).
   PubMed Web of Science ®Google Scholar
• Papayannopoulou T, Priestley GV, Nakamoto B, Zafiropoulos V, Scott LM. Molecular pathways in bone marrow homing: dominant role of α(4)β(1) over β(2)-integrins and selectins. Blood98(8), 2403–2411 (2001).
   PubMed Web of Science ®Google Scholar
• Green D, Karpatkin S. Effect of cancer on platelets. In: Coagulation in Cancer (Cancer Treatment and Research Series, Volume 148). Kwaan HC, Green D (Eds). Springer, NY, USA 148(1) (2009).
   Google Scholar
• Oku T, Tjuvajev JG, Miyagawa T et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res.58(18), 4185–4192 (1998).
   PubMed Web of Science ®Google Scholar
• Li Y, Wang MN, Li H et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med.195(12), 1575–1584 (2002).
   PubMed Web of Science ®Google Scholar
• Varker KA, Biber JE, Kefauver C et al. A randomized Phase 2 trial of bevacizumab with or without daily low-dose interferon α-2β in metastatic malignant melanoma. Ann. Surg. Oncol.14(8), 2367–2376 (2007).
   PubMed Web of Science ®Google Scholar
• Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment group study, N047A. Cancer115(1), 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Kim KB, Sosman JA et al. BEAM: a randomized Phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untrated advanced melanoma. Eur. J. Cancer Suppl.7(3), (2009) (Abstract 23LBA).
   Google Scholar
• Corrie P, Marshall A, East C et al. Safety of adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence. 7th World Congress on Melanoma Vienna, Austria 12–16 May 2009.
   Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64(19), 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol.27, 2823–2830 (2009).
   PubMed Web of Science ®Google Scholar
• Amaravadi R, Schuchter L, Kramer A et al. Preliminary results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J. Clin. Oncol.24(18S), (2006) (Abstract 8009).
   Google Scholar
• Amaravadi R, Schuchter L, McDermott D et al. Updated results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J. Clin. Oncol.25(18S), (2007) (Abstract 8527).
   Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18(1), 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Robert C, Lazar V, Lacroix L et al. Phase I/II study of the association of sorafenib and temozolimide (extended schedule) in patients with metastatic melanoma: a new clinical response profile with massive tumor necroses. J. Clin. Onc.27(15S), (2009) (Abstract 9062).
   Google Scholar
• McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J. Clin. Oncol.26(13), 2178–2185 (2008).
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol.8(11), 975–984 (2007).
   PubMed Web of Science ®Google Scholar
• Fruehauf J, Lutzky J, McDermott D et al. Axitinib (AG-013736) in patients with metastatic melanoma: a Phase II study. J. Clin. Oncol.26, (2008) (Abstract 9006).
   Web of Science ®Google Scholar
• Cook N, Kareclas P, Mann C et al. A Phase II study of PTK787 in patients with metastatic melanoma (CAMEL02). National Cancer Research Institute Cancer Conference (2008) (Abstract BOA20).
   Google Scholar
• Sini P, Wyder L, Schnell C et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin. Cancer Res.11(12), 4521–4532 (2005).
   PubMed Web of Science ®Google Scholar
• Wyman K, Spigel D, Puzanov I et al. A multicenter Phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18S), (2007) (Abstract 8539).
   Google Scholar
• Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized Phase II study. J. Clin. Oncol.27(15), 2523–2529 (2009).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer92(8), 1398–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.24(26), 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Becker JC, Brocker EB, Schadendorf D, Ugurel S. Imatinib in melanoma: a selective treatment option based on KIT mutation status? J. Clin. Oncol.25(7), (2007) (Abstract E9).
   Google Scholar
• Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res.13(19), 5670–5674 (2007).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• King AJ, Patrick DR, Batorsky RS et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res.66(23), 11100–11105 (2006).
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman J et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27(15S), (2009) (Abstract 9000).
   PubMed Web of Science ®Google Scholar
• Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS. Treatment of metastatic melanoma with an orally available inhibitor of the Ras–Raf–MAPK cascade. Cancer Res.63(18), 5669–5673 (2003).
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei AA, Lorusso PM et al. Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol.22(22), 4456–4462 (2004).
   PubMed Web of Science ®Google Scholar
• Dummer R, Robert C, Chapman PB et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, Phase II study. J. Clin. Oncol.26(26 Suppl.), (2008).
   Web of Science ®Google Scholar
• Rao RD, Winschitl HE, Allred JB et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J. Clin. Oncol.24(18S), (2006) (Abstract 8043).
   Google Scholar
• Chirivi RG, Garofalo A, Crimmin MJ et al. Inhibition of the metastatic spread and growth of B16–BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer58(3), 460–464 (1994).
   PubMed Web of Science ®Google Scholar
• Quirt I, Bodurth A, Lohmann R et al. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials group. Invest. New Drugs20(4), 431–437 (2002).
   PubMed Web of Science ®Google Scholar
• Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer2(9), 657–672 (2002).
   PubMed Web of Science ®Google Scholar
• Palavalli LH, Prickett TD, Wunderlich JR et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat. Genet.41(5), 518–520 (2009).
   PubMed Web of Science ®Google Scholar
• Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of Phase I or the termination of Phase III clinical trials. Cancer Metastasis Rev.22(2–3), 177–203 (2003).
   PubMed Web of Science ®Google Scholar
• Gutheil JC, Campbell TN, Pierce PR et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin. Cancer Res.6(8), 3056–3061 (2000).
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Algarra SM, Bastholt L et al. Immunotherapy of distant metastatic disease. Ann. Oncol.20(Suppl. 6), VI41–VI50 (2009).
   PubMed Web of Science ®Google Scholar
• Trikha M, Zhou Z, Nemeth JA et al. CNTO 95, a fully human monoclonal antibody that inhibits av integrins, has antitumor and antiangiogenic activity in vivo.Int. J. Cancer110(3), 326–335 (2004).
   PubMed Web of Science ®Google Scholar
• Mullamitha SA, Ton NC, Parker GJ et al. Phase I evaluation of a fully human anti-αv integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res.13(7), 2128–2135 (2007).
   PubMed Web of Science ®Google Scholar
• Loquai C, Pavlick A, Lawson D et al. Randomized Phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results. J. Clin. Oncol.27(15 Suppl.), (2009).
   Google Scholar
• Tentori L, Dorio AS, Muzi A et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol. Rep.19(4), 1039–1043 (2008).
   PubMed Web of Science ®Google Scholar
• Kim K, Diwan A, Papadopoulos N et al. A randomized Phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM). J. Clin. Oncol.25(18S ), (2007) (Abstract 8548).
   Google Scholar
• Kuwada SK. Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr. Opin. Mol. Ther.9(1), 92–98 (2007).
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon α-2β versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet372(9633), 117–126 (2008).
   PubMed Web of Science ®Google Scholar
• Bouwhuis MG, Suciu S, Collette S et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J. Natl Cancer Inst.101(12), 869–877 (2009).
   PubMedGoogle Scholar
• Sondak VK, Flaherty LE. Adjuvant therapy of melanoma: is pegylated interferon α-2β what we've been waiting for? Lancet372(9633), 89–90 (2008).
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Testori A, Marsden J et al. Utility of adjuvant systemic therapy in melanoma. Ann. Oncol.20(Suppl. 6), VI30–VI34 (2009).
   PubMed Web of Science ®Google Scholar
• Dinney CP, Bielenberg DR, Perrotte P et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res.58(4), 808–814 (1998).
   PubMed Web of Science ®Google Scholar
• Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science208(4443), 516–518 (1980).
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs7(6), 522–528 (2006).
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat. Rev. Cancer5(6), 423–435 (2005).
   PubMed Web of Science ®Google Scholar
• Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am. J. Pathol.170(1), 1–15 (2007).
   PubMed Web of Science ®Google Scholar
• Patnaik A, Chiorean E, Tolcher A et al. EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: results of a Phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J. Clin. Oncol.27(15s), (2009) (Abstract 2564).
   PubMedGoogle Scholar
• Hewitson KS, Schofield CJ. The HIF pathway as a therapeutic target. Drug Discov. Today9(16), 704–711 (2004).
   PubMed Web of Science ®Google Scholar
• Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today12(19–20), 853–859 (2007).
   PubMed Web of Science ®Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer2(10), 727–739 (2002).
   PubMed Web of Science ®Google Scholar
• Gourley M, Williamson JS. Angiogenesis: new targets for the development of anticancer chemotherapies. Curr. Pharm. Des.6(4), 417–439 (2000).
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res.68(14), 5501–5504 (2008).
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell15(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell15(3), 232–239 (2009).
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol.6(6), 327–338 (2009).
   PubMed Web of Science ®Google Scholar
• Jilaveanu L, Zito C, Lee SJ et al. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin. Cancer Res.15(3), 1076–1085 (2009).
   PubMed Web of Science ®Google Scholar
• Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer6(11), 835–845 (2006).
   PubMed Web of Science ®Google Scholar
• Bono A, Quarna J, Marighetti P et al. Taxanes induce a rapid mobilization of different populations of circulating endothelial progenitors by SDF-1 modulation in cancer patients. 50th ASH Annual Meeting and Exposition (2008) (Abstract 1885).
   Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003)
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cao M, Viteri S, Diaz-Lagares A et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology74, 12–16 (2008).
   PubMed Web of Science ®Google Scholar
• Peyton J, Spigel DR, Burris HA et al. Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: preliminary results. J. Clin. Oncol.27, (2009) (Abstract 9027).
   Google Scholar
• Boasberg P, Cruickshank S, Hamid O, O’Day S, Weber R, Spitler L. Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. J. Clin. Oncol.27, (2009) (Abstract 9061).
   PubMedGoogle Scholar
• Munzone E, Testori A, Minchella I et al. A Phase II trial of dacarbazine (DTIC) and bevacizumab in patients with metastatic melanoma. J. Clin. Oncol.25, (2007) (Abstract 8579).
   Google Scholar
• Wyman K, Spigel D, Puzanov I et al. A multicenter Phase II study of erlotinib and bevacizumab in patients with metastatic melanoma. J. Clin. Oncol.25, 18S (2007) (Abstract 8539).
   Google Scholar
• McClay E, Bessudo A, Frakes L et al. A Phase I/II trial of the combination of bevacizumab, oxaliplatin, and sorafenib in patients with metastatic melanoma. J. Clin. Oncol.26 (2008) (Abstract 20020).
   Google Scholar